Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05950529 · ClinicalTrials.gov registry record · NA
Clinical Study of the Effect of Two Experimental Lozenges on Oral Malodor After Single Use
A NA study of Oral Malodor, sponsored by Novozymes A/S.
- Completed
- Registry status
- NA
- Development phase
- 156
- Enrollment target
- 1
- Study location
NCT05950529: Completed NA study of Oral Malodor, sponsored by Novozymes A/S.
NCT05950529 is a NA study of Oral Malodor that has completed, run by Novozymes A/S. The registered enrollment target is 156 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05950529, a NA study of Oral Malodor, has completed, sponsored by Novozymes A/S.
- COMPLETED
- Registry status
- NA
- Development phase
- 156 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to compare the control of oral malodor between an investigational lozenge with the enzyme polyphenol oxidase plus green coffee extract or an investigational lozenge with color and flavor along with the enzyme polyphenol oxidase plus green coffee extract in generally healthy subjects. Safety will be evaluated also. Subjects will be randomly assigned to one of four study groups (group code: A, B, C or D): * Experimental lozenge with the enzyme Polyphenol oxidase and green coffee extract * Experimental lozenge with the enzyme Polyphenol oxidase, green coffee extract and flavor * Placebo lozenge control (sorbitol only) * No product control Subjects will be asked to allow their assigned lozenge to dissolve in the mouth while placed on the dorsal surface of the tongue. Subjects can suck on the lozenge and press the lozenge against the palate; however, the lozenge should not be moved around in the mouth or placed on the buccal mucosa. Subjects should avoid biting or chewing the lozenge and talking while dissolving the lozenge. After the lozenge has completely dissolved, the subject will be instructed to swallow the remaining solution. Immediately (no later than 5 minutes) after subjects use their assigned lozenge product or no product, subjects will receive organoleptic assessments (OI) by the 4-5 trained judges and VSC readings (OralChroma readings). Organoleptic measurements (OI) will be repeated at 30 minutes, 1, 2, 3, and 4 hours following test product use or no test product use. OralChroma measurements will be performed again after 30 minutes, 1, 2, 3, and 4 hours after test product use or no test product. Subjects will complete a post-product performance questionnaire after the 1-hour OI and OralChroma assessments have been administered. Following the 4-hour OralChroma assessment, each subject will receive a final oral soft and hard tissue exam for safety.
Primary Outcome
The mean total VSC (OralChroma) readings from the Baseline assessment to the immediate (5 minutes) assessment following product use.
Conditions Studied
Interventions
- OTHER Experimental lozenge with the enzyme Polyphenol oxidase and green coffee extract
- OTHER Experimental lozenge with the enzyme Polyphenol oxidase, green coffee extract and flavor
- OTHER Placebo lozenge control (sorbitol only)
- OTHER No product
Study Locations (1)
Indiana
- Salus Research - Fort Wayne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2020-02-06 |
| Est. Completion | 2020-03-11 |
| Phase | NA |
What the finished NCT05950529 record still lists
NCT05950529 is an interventional study that assigns participants to a tested intervention. The registered 156 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Oral Malodor appearing as the primary indexed condition, and to 4 interventions - of which Experimental lozenge with the enzyme Polyphenol oxidase and green coffee extract is the first listed.
NCT05950529 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT05950529 about?
NCT05950529 is a clinical study titled "Clinical Study of the Effect of Two Experimental Lozenges on Oral Malodor After Single Use". The goal of this clinical trial is to compare the control of oral malodor between an investigational lozenge with the enzyme polyphenol oxidase plus green coffee extract or an investigational lozenge with color and flavor along with the enzyme polyphenol oxidase plus green coffee extract in generall...
What is the current status of trial NCT05950529?
This trial is currently completed. It is a NA study. The enrollment target is 156 participants. The study started on 2020-02-06. Estimated completion is 2020-03-11.
What conditions does trial NCT05950529 study?
This clinical trial studies the following conditions: Oral Malodor.
What interventions are being tested in trial NCT05950529?
The interventions under investigation include: Experimental lozenge with the enzyme Polyphenol oxidase and green coffee extract (OTHER), Experimental lozenge with the enzyme Polyphenol oxidase, green coffee extract and flavor (OTHER), Placebo lozenge control (sorbitol only) (OTHER), No product (OTHER).
Who is sponsoring clinical trial NCT05950529?
This trial is sponsored by Novozymes A/S, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05950529 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05950529's enrollment target sits among peer trials
156 656th of 2000 higher than 1,345 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03082755 · 156 participants · Phase 4
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
- NCT04047628 · 156 participants · Phase 3
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
- NCT04166877 · 156 participants · Phase 4
Magnesium Infusion for Pain Management in Critically Ill Trauma Patients
- NCT04533464 · 156 participants · Phase 2
MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI